GLP-1 microdosing and the compounding reality.
Two topics dominate GLP-1 discussion outside clinical settings: taking less than the labeled amount, usually called microdosing, and obtaining the drug from a compounding pharmacy rather than as the approved product. Both are widely discussed and poorly documented. This guide explains what people mean by microdosing, why the approved labels escalate the way they do, what compounding actually is under United States law, how the drug shortage list created the compounded GLP-1 market and what happened when it ended, and what the specific documented risks are. It contains no schedules, protocols, or amounts.
Reviewed June 1, 2026
- Microdosing is not a labeled or studied strategy. No approved GLP-1 label describes it, and the pivotal trials tested the escalation schedules and maintenance dosages that appear in the labels, not smaller ones held indefinitely.
- The labeled escalations exist for a stated reason. Both the Wegovy and Zepbound labels instruct prescribers to follow the escalation “to reduce the risk of gastrointestinal adverse reactions.”
- Compounding is regulated in two tiers: 503A state-licensed pharmacies compounding for identified patients, and 503B outsourcing facilities registered with FDA and subject to CGMP.
- The compounded GLP-1 market existed largely because semaglutide and tirzepatide were on FDA's drug shortage list. FDA declared the tirzepatide shortage resolved on 2 October 2024 and the semaglutide shortage resolved on 21 February 2025, and the enforcement discretion periods that followed have ended.
- Salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients from the base form in the approved drugs, and FDA has stated it is not aware of any lawful basis for their use in compounding.
What people mean by microdosing.
Microdosing, in this context, refers to deliberately using an amount below the maintenance dosage that appears in the approved label, and staying there rather than escalating. The stated motivations vary: reducing gastrointestinal side effects, preserving lean mass, making a supply last longer, managing cost, or attempting to keep some benefit after reaching a target weight. Those are all coherent motivations. None of them is the same thing as evidence that the approach works.
The term itself is borrowed and slightly misleading. It carries an implication, from other contexts, that a small amount produces a distinct and intentional effect. In the GLP-1 case what is being described is simply a sub-maintenance amount used as a maintenance strategy, which is a different concept and one the trials did not test.
Why the approved labels escalate the way they do.
The escalation schedules are public regulatory facts and worth stating plainly, because a lot of speculation about them is unnecessary. The labels say why they exist.
The Wegovy injection prescribing information sets a starting dosage of 0.25 mg subcutaneously once weekly and instructs prescribers to follow the dosage escalation table “to reduce the risk of gastrointestinal adverse reactions.” The published table runs 0.25 mg for weeks 1 through 4, 0.5 mg for weeks 5 through 8, 1 mg for weeks 9 through 12, 1.7 mg for weeks 13 through 16, and the maintenance dosage from week 17 onward, with 2.4 mg once weekly as the usual recommended maintenance dosage. The label adds that if a patient does not tolerate a dose during escalation, escalation may be delayed for four weeks.
The Zepbound label follows the same logic with different numbers. The recommended starting dosage is 2.5 mg subcutaneously once weekly for four weeks, and the label states explicitly that “the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.” It then instructs prescribers to follow the escalation, again “to reduce the risk of gastrointestinal adverse reactions,” increasing to 5 mg after four weeks and thereafter in 2.5 mg increments after at least four weeks on the current dose, with maintenance dosages of 5 mg, 10 mg, or 15 mg and a maximum of 15 mg once weekly.
- 01They are tolerability ramps, not efficacy ramps. Both labels give the same stated purpose: reducing gastrointestinal adverse reactions. The starting amounts exist so people can reach the studied maintenance dosage without stopping because of nausea.
- 02The starting dosage is explicitly not a maintenance dosage. The Zepbound label states this in so many words about 2.5 mg. That is a direct regulatory statement about the question microdosing raises.
- 03They build in flexibility for tolerability. Both labels contemplate slowing escalation or selecting a lower maintenance dosage based on tolerability, which is a prescriber decision made within the labeled range, not the same thing as an unstudied sub-maintenance strategy.
- 04The maintenance range is itself a range. Wegovy names 2.4 mg as the usual recommended maintenance dosage with 1.7 mg named for one indication, and Zepbound names 5, 10, or 15 mg. Lower labeled maintenance options exist and are studied. Amounts below the labeled range are a different situation.
The trials tested the target dosages, not a lower plateau.
Every headline efficacy number people cite for these drugs comes from a trial in which participants escalated to a target maintenance dosage and stayed there. STEP 1 randomised participants to semaglutide 2.4 mg once weekly for 68 weeks, including 16 weeks of dose escalation, and reported a mean weight change of -14.9% versus -2.4% with placebo. SURMOUNT-1 randomised to tirzepatide 5, 10, or 15 mg once weekly for 72 weeks, reporting -15.0%, -19.5%, and -20.9% respectively versus -3.1% with placebo.
Those trials do establish a dose response: 15 mg outperformed 5 mg in SURMOUNT-1. What they do not establish is what happens when someone holds an amount below the lowest studied maintenance dosage indefinitely. The honest position is that the question has not been answered by randomised evidence, and inferring an answer by extrapolating below the bottom of a dose response curve is not a safe inference.
- 01Efficacy. The magnitude of weight change at sub-maintenance amounts held long term has not been characterised in randomised trials.
- 02Durability. The withdrawal trials show that weight regain begins promptly when treatment stops. Whether a reduced amount prevents regain the way a maintenance dosage does is a separate question with separate evidence needs.
- 03Safety. Adverse reaction profiles in the labels are derived from the studied schedules. A different exposure pattern is not automatically safer merely because the amount is smaller.
- 04Measurement. Any personal conclusion drawn from trying it is subject to the same problems described in the results and timelines guide: no control arm, no blinding, and regression to the mean.
What compounding actually is.
Compounding is the preparation of a drug by combining, mixing, or altering ingredients to create a medication tailored to an individual patient's needs. It is a long-standing and legitimate pharmacy practice, and in the United States it is regulated in two distinct tiers under the Federal Food, Drug, and Cosmetic Act. The critical point for anyone evaluating a compounded product is that compounded drugs are not FDA-approved. They do not go through premarket review for safety, effectiveness, or quality.
- 01Section 503A: traditional compounding pharmacies. State-licensed pharmacies or physicians compounding for an identified individual patient pursuant to a valid prescription. They are exempt from certain FD&C Act requirements, including FDA approval and, notably, current good manufacturing practice requirements. They are primarily overseen by state boards of pharmacy rather than by FDA inspection.
- 02Section 503B: outsourcing facilities. Facilities that register with FDA, may compound in larger volumes without patient-specific prescriptions, are subject to CGMP requirements, are inspected by FDA on a risk-based schedule, and must report adverse events to FDA. They may only compound from bulk drug substances that appear on FDA's 503B bulks list or that are on the drug shortage list at the time of compounding.
- 03The essential copies restriction. Neither tier may routinely compound a drug that is essentially a copy of a commercially available FDA-approved product. FDA has described considerations including whether the products use the same route of administration and whether the strengths are the same, similar, or easily substitutable, and has stated it considers strengths within 10% of the commercially available product in that light for certain semaglutide combinations.
- 04Adverse event reporting is asymmetric. FDA has stated that federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA, so adverse events from 503A-compounded versions are likely underreported.
How the shortage list created the compounded GLP-1 market.
The bridge between compounding law and the GLP-1 boom is the drug shortage list. Both the essentially-a-copy restriction under 503A and the bulk drug substance restriction under 503B have carve-outs that depend on a drug being on FDA's shortage list. When semaglutide and tirzepatide injection products went into shortage under surging demand, those carve-outs opened, and a very large compounded market grew inside them, frequently marketed direct to consumers through telehealth.
That basis was always contingent on the shortage continuing, and it did not. FDA determined the tirzepatide injection shortage resolved on 2 October 2024, and determined the semaglutide injection shortage resolved on 21 February 2025, confirming with the manufacturers that stated availability and manufacturing capacity could meet present and projected national demand. FDA then set defined periods during which it did not intend to take action against compounders for violations arising from conditions that depended on inclusion on the shortage list. Litigation followed in both cases, and in both the district court denied the plaintiffs' preliminary injunction motions.
- 012 October 2024. FDA determines the tirzepatide injection product shortage is resolved. The decision was subsequently remanded to the agency for reevaluation as part of litigation before being reaffirmed.
- 0221 February 2025. FDA determines the semaglutide injection product shortage is resolved.
- 035 March 2025. The district court denies the preliminary injunction motion regarding tirzepatide. The 503A enforcement discretion period ends; the 503B period runs to 19 March 2025.
- 0424 April 2025. The district court denies the preliminary injunction motion regarding semaglutide. The 503A enforcement discretion period ends; the 503B period runs to 22 May 2025.
- 05Current status. FDA states that tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list. FDA has separately proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list.
Salt forms are not the approved molecule.
A recurring and specific issue is the use of semaglutide salt forms. The approved products contain the base form of semaglutide. Some compounded products have used salt forms instead, most commonly semaglutide sodium and semaglutide acetate.
FDA's position on this is unambiguous. The agency states that these salt forms are different active ingredients than are used in the approved drugs, that it does not have information on whether these salts have the same chemical and pharmacologic properties as the active ingredient in the approved drug, and that it is not aware of any lawful basis for their use in compounding. This is a chemistry statement as much as a legal one: a salt of a molecule is not automatically interchangeable with the base form in potency, solubility, or stability, and demonstrating equivalence requires data that does not exist here.
The specific documented risks.
These are not hypothetical concerns. FDA has published a specific alert about dosing errors with compounded injectable semaglutide, and the mechanism it describes is worth understanding because it explains why the compounded format itself creates risk independent of the molecule.
- 01Concentration is not standardised. FDA states that product concentrations may vary depending on the compounder, and that a single compounder may offer multiple concentrations of compounded semaglutide. The approved injection products deliver preset amounts from a pen. A vial does not.
- 02Unit confusion. FDA describes instructions that direct users to administer in “units,” the volume of which varies with concentration, rather than in milligrams or millilitres, and identifies confusion between millilitres, milligrams, and units as a contributor to dosing errors. This is exactly the syringe-unit trap covered in the reconstitution guide.
- 03Inexperience with vial technique. FDA notes that many patients who received vials of compounded semaglutide lacked experience with self-injection and with withdrawing medication from a vial into a syringe.
- 04Oversized syringes. FDA reports instances in which patients were given syringes significantly larger than the prescribed volume, which makes small-volume measurement error much more likely.
- 05No FDA premarket review. Compounded drugs do not undergo FDA premarket review for safety, quality, or effectiveness. There is no approval package establishing that a given compounded preparation delivers what its label says.
- 06Weaker release and quality assurance under 503A. Traditional compounding pharmacies are exempt from CGMP requirements. Lot-level release testing, stability data, and sterility assurance comparable to an approved manufacturer are not guaranteed.
- 07Recall and reporting gaps. Federal law does not require non-outsourcing state-licensed pharmacies to report adverse events to FDA, so signals are underreported and there is no equivalent of a manufacturer-wide recall mechanism across an unstandardised market.
- 08Prolonged consequences of an overdose. FDA notes that a prolonged period of observation and treatment may be necessary due to the long half-life of semaglutide of about one week. An overdose is not something that resolves in hours.
The reported volume is not trivial. FDA states that as of 31 May 2026 it had received 990 reports of adverse events associated with compounded semaglutide and more than 730 reports associated with compounded tirzepatide, while noting that it is not always possible to determine whether an adverse event resulted directly from the drug and that underreporting is likely. FDA has also received reports that may relate to patients being prescribed compounded semaglutide or tirzepatide in amounts beyond what is in the FDA-approved label, including using more product in a single administration, administering more frequently, or increasing the amount more quickly than the labeled titration schedule.
How to think about this honestly.
The compounded GLP-1 story is not a simple one where every party behaved badly. There was a genuine shortage, there was genuine unmet demand at a price people could pay, and compounding under the shortage carve-out was a lawful response to it at the time. What has changed is that the shortage is over, the carve-outs closed, and a market built on a temporary legal basis did not entirely wind down with it.
- 01Is it the approved product or a compounded preparation? These are different regulatory categories with different levels of evidence behind them, and the distinction is not always obvious from marketing.
- 02If compounded, under which section? A 503B outsourcing facility is FDA-registered, CGMP-subject, inspected, and required to report adverse events. A 503A pharmacy is none of those things. FDA publishes a list of registered outsourcing facilities.
- 03What is the concentration, in mg per mL? Without that number, no volume means anything. This is the single most common source of the dosing errors FDA has documented.
- 04Is it the base molecule? Salt forms such as semaglutide sodium and semaglutide acetate are, per FDA, different active ingredients from the one in the approved drugs.
- 05Is there a lawful basis at all? Since the shortages resolved, “compounded because of the shortage” is no longer accurate. Compounding for a documented individual clinical need that no approved product can meet is a genuinely different case from mass substitution.
- 06Who is accountable if something goes wrong? Approved products have a manufacturer, a label, a pharmacovigilance system, and a recall pathway. A gray-market vial has none of those.
FAQ.
What is GLP-1 microdosing?
It refers to deliberately using an amount below the maintenance dosage in the approved label and staying there rather than escalating. It is not a labeled or studied strategy: no approved GLP-1 label describes it, and the pivotal trials tested the labeled escalation schedules and maintenance dosages. Its efficacy, durability, and safety at sub-maintenance amounts held long term have not been characterised in randomised trials.
Why do the approved labels escalate the dose over several months?
Both labels state the reason directly. The Wegovy injection label instructs prescribers to follow the escalation table 'to reduce the risk of gastrointestinal adverse reactions,' and the Zepbound label uses the same language. The starting amounts exist so that people can reach the studied maintenance dosage without discontinuing because of nausea and related effects. The Zepbound label also states that its 2.5 mg starting dosage is not approved as a maintenance dosage.
Is a lower dose safer?
Not automatically, and it is not established either way. The adverse reaction profiles in the labels come from the studied schedules, so a different exposure pattern has a different and largely uncharacterised profile rather than a known safer one. Both labels do contemplate slowing escalation or choosing a lower labeled maintenance dosage for tolerability, but that is a prescriber decision within the studied range, which is a different situation from an unstudied sub-maintenance plateau.
What is the difference between a 503A pharmacy and a 503B outsourcing facility?
A 503A pharmacy is state-licensed, compounds for an identified patient against a valid prescription, is exempt from current good manufacturing practice requirements, and is not required by federal law to report adverse events to FDA. A 503B outsourcing facility registers with FDA, may compound in larger volumes without patient-specific prescriptions, is subject to CGMP, is inspected by FDA, and must report adverse events. Neither produces an FDA-approved drug.
Why was compounded semaglutide legal and what changed?
Both the essentially-a-copy restriction for 503A and the bulk drug substance restriction for 503B have carve-outs tied to a drug being on FDA's shortage list. Semaglutide and tirzepatide injection products were in shortage, which opened those carve-outs. FDA determined the tirzepatide shortage resolved on 2 October 2024 and the semaglutide shortage resolved on 21 February 2025, courts denied the compounders' preliminary injunction motions, and the enforcement discretion periods that followed have ended.
Is semaglutide sodium the same as semaglutide?
No. FDA states that salt forms including semaglutide sodium and semaglutide acetate are different active ingredients than are used in the approved drugs, that it does not have information on whether these salts share the same chemical and pharmacologic properties as the approved active ingredient, and that it is not aware of any lawful basis for their use in compounding. The approved products contain the base form.
What are the actual documented risks of compounded GLP-1 products?
FDA has published a specific alert on dosing errors with compounded injectable semaglutide, some requiring hospitalisation. The contributing factors it identifies are concentrations that vary between compounders and even within one compounder, instructions given in 'units' whose volume depends on concentration, patients unfamiliar with drawing from a vial, and syringes significantly larger than the prescribed volume. Compounded drugs also do not undergo FDA premarket review for safety, quality, or effectiveness.
How many adverse events have been reported for compounded GLP-1 products?
FDA states that as of 31 May 2026 it had received 990 reports of adverse events associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. FDA also notes that causation cannot always be determined and that, because state-licensed pharmacies that are not outsourcing facilities are not federally required to report, these numbers are likely an undercount.
Is 'research use only' semaglutide a legitimate alternative?
No. That material sits outside both the approved-drug system and the compounding framework. FDA has warned companies illegally selling unapproved drugs containing semaglutide, has issued an import alert covering GLP-1 active pharmaceutical ingredients with potential quality concerns, and is aware of fraudulent compounded products carrying false label information as well as counterfeit Ozempic in the United States. The research-use label describes the seller's legal posture, not product quality.
Why does concentration matter so much with a compounded vial?
Because a volume only means something once you know the concentration. The approved injection products deliver preset amounts from a pen; a vial requires the user to measure. FDA reports that concentrations vary between compounders and that a single compounder may offer several, and it identifies confusion between millilitres, milligrams, and syringe 'units' as a direct contributor to overdoses. Any compounded vial should have its mg per mL clearly stated.
Sources.
- [1]FDA: FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (salt forms, dosing concerns, adverse event counts, counterfeits) · U.S. Food and Drug Administration
- [2]FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (shortage resolution dates and enforcement discretion timelines) · U.S. Food and Drug Administration
- [3]FDA: FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products · U.S. Food and Drug Administration
- [4]FDA: Compounding when Drugs are on FDA's Drug Shortages List · U.S. Food and Drug Administration
- [5]FDA: Compounding and the FDA: Questions and Answers · U.S. Food and Drug Administration
- [6]FDA: Human Drug Compounding Laws and Policies (sections 503A and 503B of the FD&C Act) · U.S. Food and Drug Administration
- [7]FDA: Information for Outsourcing Facilities (503B registration, CGMP, adverse event reporting) · U.S. Food and Drug Administration
- [8]FDA: Registered Outsourcing Facilities list · U.S. Food and Drug Administration
- [9]FDA: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List · U.S. Food and Drug Administration
- [10]WEGOVY (semaglutide) prescribing information: recommended starting dosage and dosage escalation table · FDA / DailyMed
- [11]ZEPBOUND (tirzepatide) prescribing information: recommended dose escalation schedule and maintenance dosage · FDA / DailyMed
- [12]Wilding JPH et al.: Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) · N Engl J Med, 2021 (PMID 33567185)
- [13]Jastreboff AM et al.: Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) · N Engl J Med, 2022 (PMID 35658024)
Cite this page
PepCue. “GLP-1 microdosing and the compounding reality.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/guides/glp1-microdosing-and-compounding.
Track your protocol in PepCue.
Log doses, run the calculators, follow the evidence, and keep peptides, GLP-1s, TRT and labs in one private timeline.